FDA reviewing Merck's experimental insomnia drug

by The Associated Press

(AP)—Drugmaker Merck & Co. says the Food and Drug Administration is reviewing its experimental insomnia medication, suvorexant (SOO'vor-eks-ant).

The drug minimizes the morning grogginess common with many sleep aids. It could become a big seller for the Whitehouse Station, N.J., company.

If approved, it would be the first in a new class of medicines for patients with trouble falling or staying asleep. It works by temporarily blocking chemical messengers that keep people awake.

The FDA is doing a standard review, which usually takes 10 months. If approved, suvorexant would be a controlled substance like all hypnotic sleep drugs. They require additional government reviews taking four months or longer.

In studies, suvorexant's most common side effects were tiredness and headache.

also plans to seek approval for suvorexant in other countries.

0 shares

Related Stories

FDA won't accept Merck's application for new drug

date Nov 02, 2009

(AP) -- U.S. regulators have refused to accept drugmaker Merck & Co.'s application for a new, combination cholesterol pill that includes rival Pfizer's Lipitor, the world's top-selling drug.

FDA links some prostate drugs to cancer risk

date Jun 09, 2011

(AP) -- The Food and Drug Administration expanded the warning label on a group of prostate drugs Thursday, saying they may increase the risk of a more serious form of prostate cancer.

FDA says Merck drug successfully fights hepatitis

date Apr 25, 2011

Federal health officials said Monday a highly-anticipated drug to treat hepatitis C made by Merck appears to cure more patients in less time than established drugs that have been used for 20 years. But the agency has questions ...

Recommended for you

Rising antibiotic shortages raise concerns about patient care

date Apr 23, 2015

Shortages of key antibiotics, including gold-standard therapies and drugs used to treat highly resistant infections, are on the rise, according to a new study of shortages from 2001 to 2013 published in Clinical Infectious Di ...

Study supports HPV vaccination guidelines

date Apr 21, 2015

(HealthDay)—New research finds that young women who get the HPV vaccine gain significant protection against infection in three parts of the body if they haven't already been exposed to the human papillomavirus.

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.